{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:04:25Z","timestamp":1787900665808,"version":"build-2784847793"},"reference-count":391,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.plipres.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T05:04:10Z","timestamp":1475730250000},"page":"192-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'"],"prefix":"10.1016","volume":"64","author":[{"given":"Naseem","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riaz A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plipres.2016.08.005_bb0005","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/jid.2010.205","article-title":"X-linked inhibitor of apoptosis protein as a therapeutic target in metastatic melanoma","volume":"130","author":"Tian","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0001-2092(06)61577-9","article-title":"Surgical treatment of nonmelanoma skin cancer","volume":"71","author":"Anthony","year":"2000","journal-title":"AORN"},{"key":"10.1016\/j.plipres.2016.08.005_bb0015","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.mcna.2009.08.011","article-title":"Malignant skin neoplasms","volume":"93","author":"Ricotti","year":"2009","journal-title":"Med. Clin. North. Am."},{"key":"10.1016\/j.plipres.2016.08.005_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1040-8428(01)00185-8","article-title":"Chemoprevention of human skin cancer","volume":"41","author":"Einspahr","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1751-1097.1990.tb08452.x","article-title":"Molecular mechanism of ultraviolet radiation carcinogenesis","volume":"52","author":"Ananthaswamy","year":"1990","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0035","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/clinchem\/41.12.1854","article-title":"DNA repair and epidemiology of basal cell carcinoma","volume":"41","author":"Grossman","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2003.09.002","article-title":"Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters","volume":"56","author":"Lopez","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0001-7310(07)70133-3","article-title":"Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current","volume":"98","author":"Barrera","year":"2007","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.plipres.2016.08.005_bb0050","doi-asserted-by":"crossref","first-page":"e102664","DOI":"10.1371\/journal.pone.0102664","article-title":"Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation","volume":"15","author":"Stein","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2016.08.005_bb0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.det.2011.01.011","article-title":"Nonsurgical treatment of nonmelanoma skin cancer","volume":"29","author":"Galiczynski","year":"2011","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.plipres.2016.08.005_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/mf.2008.30.4.1185802","article-title":"Antipsoriatic microemulsion gel formulations for topical drug delivery of babchi oil (Psoralea corylifolia)","volume":"30","author":"Ali","year":"2008","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejpb.2010.02.007","article-title":"Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging","volume":"75","author":"Goutayer","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2009.06.001","article-title":"Lipid-an emerging platform for oral delivery of drugs with poor bioavailability","volume":"73","author":"Chakraborty","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.addr.2007.09.010","article-title":"Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective","volume":"60","author":"Chen","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.plipres.2016.08.005_bb0085","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1166\/jbn.2013.1613","article-title":"Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation","volume":"9","author":"Akhtar","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"issue":"5","key":"10.1016\/j.plipres.2016.08.005_bb0090","first-page":"348","article-title":"Production, characterization, in vitro and ex vivo studies of babchi oil-encapsulated nanostructured solid lipid carriers produced by a hot aqueous titration method","volume":"65","author":"Faiyazuddin","year":"2010","journal-title":"Pharmazie"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-409X(96)00490-5","article-title":"Formulation of self emulsifying drug delivery systems","volume":"25","author":"Pouton","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0100","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: non emulsifying, self emulsifying and \u2018self microemulsifying\u2019 drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3\u20134","key":"10.1016\/j.plipres.2016.08.005_bb0105","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.plipres.2016.08.005_bb0110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO;2-R","article-title":"Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts","volume":"89","author":"Charman","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0115","first-page":"1","article-title":"Topical delivery of paclitaxel for treatment of skin cancer","volume":"4","author":"Bharadwaj","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"11","key":"10.1016\/j.plipres.2016.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1166\/jbn.2015.2139","article-title":"Topical skin cancer therapy using doxorubicin-loaded cationic lipid nanoparticles and lontophoresis","volume":"11","author":"Huber","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejps.2016.01.003","article-title":"Quality by design case study 1: design of 5-fluorouracil loaded lipid nanoparticles by the W\/O\/W double emulsion \u2014 solvent evaporation method","volume":"84","author":"Amasya","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.plipres.2016.08.005_bb0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2016.03.018","article-title":"Percutaneous absorption of benzophenone-3 loaded lipid nanoparticles and polymeric nanocapsules: A comparative study","volume":"504","author":"Gilbert","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/1061186X.2014.965717","article-title":"Sesamol-loaded solid lipid nanoparticles for treatment of skin cancer","volume":"23","author":"Geetha","year":"2015","journal-title":"J. Drug Target."},{"issue":"1\u20132","key":"10.1016\/j.plipres.2016.08.005_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2015.07.013","article-title":"Optimization of nanostructured lipid carriers loaded with methotrexate: a tool for inflammatory and cancer therapy","volume":"492","author":"Ferreira","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0145","first-page":"1261","article-title":"Novel therapeutic mechanisms determine the effectiveness of lipid-core nanocapsules on melanoma models","volume":"11","author":"Drewes","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.plipres.2016.08.005_bb0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0098-2997(93)90008-2","article-title":"Control of neoplastic cell proliferation and differentiation by restoration of 4-hydroxynonenal physiological concentrations","volume":"14","author":"Fazio","year":"1993","journal-title":"Mol. Aspects Med."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2011.03.008","article-title":"Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine","volume":"79","author":"Ourique","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2011","key":"10.1016\/j.plipres.2016.08.005_bb0160","first-page":"571272","article-title":"Lipid nanocapsule-based gels for enhancement of transdermal delivery of ketorolac tromethamine","volume":"17","author":"Varshosaz","year":"2011","journal-title":"J. Drug. Deliv."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ics.12044","article-title":"Skin cell targeting with self-assembled ligand addressed nanoemulsion droplets","volume":"35","author":"Atrux-Tallau","year":"2013","journal-title":"Int. J. Cosmet. Sci."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1049\/iet-nbt.2014.0010","article-title":"In vitro cytotoxic activity of chitosan-bullfrog oil microemulsion against melanoma cells","volume":"9","author":"Bonatto","year":"2015","journal-title":"IET Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1211\/jpp.59.6.0005","article-title":"Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE)","volume":"59","author":"Suppasansatorn","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0180","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1208\/s12249-014-0278-5","article-title":"A novel topical targeting system of caffeine microemulsion for inhibiting UVB-induced skin tumor: characterization, optimization, and evaluation","volume":"16","author":"Ma","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0185","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1208\/s12249-013-0017-3","article-title":"Development of novel elastic vesicle-based topical formulation of cetirizine dihydrochloride for treatment of atopic dermatitis","volume":"14","author":"Goindi","year":"2013","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0190","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/2230-973X.107002","article-title":"Formulation and evaluation of Ketoconazole niosomal gel drug delivery system","volume":"2","author":"Shirsand","year":"2012","journal-title":"Int. J. Pharm. Investig."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0195","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1248\/bpb.b15-00750","article-title":"Skin permeation of testosterone from viscoelastic lecithin reverse wormlike micellar solution","volume":"39","author":"Imai","year":"2016","journal-title":"Biol. Pharm. Bull."},{"issue":"2\u20133","key":"10.1016\/j.plipres.2016.08.005_bb0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3923\/pjbs.2012.141.146","article-title":"Characterization and stability of nanostructured lipid carriers as drug delivery system","volume":"15","author":"Abbasalipourkabir","year":"2012","journal-title":"Pak. J. Biol. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (sln, nlc) in cosmetic andpharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0215","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5138\/ijdd.2010.0975.0215.02029","article-title":"Solid lipid nanoparticles in cancer therapy","volume":"2","author":"Mathur","year":"2010","journal-title":"Int. J. Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb0220","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0939-6411(97)00150-1","article-title":"Solid lipid nanoparticles (sln) for controlled drug delivery \u2013 drug release and release mechanism","volume":"45","author":"zur M\u00fchlen","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0225","unstructured":"Adrian F, Torsten W, Ralph L. Stabilised supersaturated solids of lipophilic drugs. USP8715736, 2005"},{"issue":"7","key":"10.1016\/j.plipres.2016.08.005_bb0230","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/acs.molpharmaceut.6b00230","article-title":"Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene: strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors","volume":"13","author":"Mondal","year":"2016","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejpb.2011.04.009","article-title":"Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers","volume":"79","author":"Abdel-Mottaleb","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0240","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijpharm.2011.06.031","article-title":"In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model","volume":"423","author":"David","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.plipres.2016.08.005_bb0245","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/jid.2010.293","article-title":"Paying \u201cparticle\u201d attention to novel melanoma treatment strategies","volume":"130","author":"Weiss","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0250","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2011.03.008","article-title":"Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine","volume":"79","author":"Ourique","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-6-8","article-title":"Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells","volume":"6","author":"Pisano","year":"2007","journal-title":"Mol. Cancer."},{"issue":"12","key":"10.1016\/j.plipres.2016.08.005_bb0265","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1166\/jbn.2015.2131","article-title":"Improved anti-tumoral therapeutic efficacy of 4-hydroxynonenal incorporated in novel lipid nanocapsules in 2D and 3D models","volume":"11","author":"Pizzimenti","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0270","unstructured":"WO2009123595A1"},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nano.2010.12.002","article-title":"A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension","volume":"7","author":"Kakumanu","year":"2011","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0280","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/17425240902967607","article-title":"Pharmacosomes: the lipid-based new drug delivery system","volume":"6","author":"Semalty","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb0285","first-page":"348186","article-title":"Pharmacosomes: an emerging novel vesicular drug delivery system for poorly soluble synthetic and herbal drugs","volume":"2013","author":"Pandit","year":"2013","journal-title":"ISRN Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0290","first-page":"39","article-title":"Herbosomes: a current concept of herbal drug technology, an overview","volume":"01","author":"Ajay","year":"2012","journal-title":"J. Medical Pharm. Allied Sci."},{"issue":"11","key":"10.1016\/j.plipres.2016.08.005_bb0295","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3109\/03639045.2012.738685","article-title":"Pharmacological evaluation of mangiferin herbosomes for antioxidant and hepatoprotection potential against ethanol induced hepatic damage","volume":"39","author":"Jain","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2013.12.003","article-title":"Can formulation and drug delivery reduce attrition during drug discovery and development\u2014review of feasibility, benefits and challenges","author":"Basvaraj","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/17425247.5.1.119","article-title":"Microemulsions as novel drug carriers: the formation, stability, applications and toxicity","volume":"5","author":"Karasulu","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2010.01.008","article-title":"Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy","volume":"75","author":"Araujo","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.foodchem.2014.01.012","article-title":"Preparation of curcumin microemulsions with food-grade soybean oil\/lecithin and their cytotoxicity on the HepG2 cell line","volume":"154","author":"Lin","year":"2014","journal-title":"Food Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb0320","doi-asserted-by":"crossref","first-page":"63013","DOI":"10.1039\/C6RA10193C","article-title":"Photodynamic inactivation against Pseudomonas aeruginosa by curcumin microemulsions","volume":"6","author":"Liu","year":"2016","journal-title":"RSC Adv."},{"issue":"1\u20132","key":"10.1016\/j.plipres.2016.08.005_bb0325","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijpharm.2007.07.022","article-title":"Transdermal delivery of capsaicin derivative-sodium nonivamide acetate using microemulsions as vehicles","volume":"349","author":"Huang","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0330","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1049\/iet-nbt.2014.0010","article-title":"In vitro cytotoxic activity of chitosan\u2013bullfrog oil microemulsion against melanoma cells","volume":"9","author":"Bonatto","year":"2015","journal-title":"IET Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0335","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.foodchem.2009.03.052","article-title":"Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsions","volume":"116","author":"Lin","year":"2009","journal-title":"Food Chem."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0340","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.colsurfb.2010.08.018","article-title":"Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants","volume":"82","author":"Liu","year":"2011","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0345","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1049\/iet-nbt.2014.0010","article-title":"In vitro cytotoxic activity of chitosan-bullfrog oil microemulsion against melanoma cells","volume":"9","author":"Bonatto","year":"2015","journal-title":"IET Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0350","first-page":"15","article-title":"Vesicular phospholipid gels: a technology platform","volume":"17","author":"Brandl","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-60327-360-2_14","article-title":"Vesicular phospholipid gels","volume":"605","author":"Brandl","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0360","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/1567201811666140924130224","article-title":"Self-emulsifying lipid formulation: an overview","volume":"12","author":"Saluja","year":"2015","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb0365","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0076-6879(05)91018-5","article-title":"Drug delivery by lipid cochleates","volume":"391","author":"Zarif","year":"2005","journal-title":"Methods Enzymol."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0370","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/nnm.10.10","article-title":"Nanomicellar formulations for sustained drug delivery: strategies and underlying principles","volume":"5","author":"Trivedi","year":"2010","journal-title":"Nanomedicine (London)"},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0375","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/2230-973X.143112","article-title":"A perspective overview on lipospheres as lipid carrier systems","volume":"4","author":"Dudala","year":"2014","journal-title":"Int. J. Pharm. Investig."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0380","article-title":"Liposphere: a versatile controlled release carrier for hydrophobic drugs","volume":"1","author":"Patra","year":"2014","journal-title":"J. Pharm. Drug Devel."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0385","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1389201016666150118134256","article-title":"Proliposomes for oral delivery: progress and challenges","volume":"16","author":"Nekkanti","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0390","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.115.012070","article-title":"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0395","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","article-title":"Oral lipid-based drug delivery systems \u2014 an overview","volume":"3","author":"Kalepu","year":"2013","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.plipres.2016.08.005_bb0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.plipres.2016.08.005_bb0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/js960085v","article-title":"Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH","volume":"86","author":"Charman","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0410","series-title":"Clinical trials of liposomes as carriers of chemotherapeutic agents: synopsis and perspective, in Medical Applications of Liposomes (Lasic DD, Papahadjopoulos D, eds)","first-page":"625","author":"Gabizon","year":"1998"},{"key":"10.1016\/j.plipres.2016.08.005_bb0415","first-page":"2","article-title":"Clinically-proven liposome-based drug delivery: formulation, characterization and therapeutic efficacy","volume":"1","author":"Chang","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.plipres.2016.08.005_bb0420","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/0024-3205(80)90268-4","article-title":"Liposomes \u2014 a selective drug delivery system for the topical route of administration: lotion dosage form","volume":"26","author":"Mezei","year":"1980","journal-title":"Life Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0425","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1468-3083.2009.03100.x","article-title":"Liposomes in dermatology today","volume":"23","author":"De Leeuw","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0430","series-title":"Liposomes: A Practical Approach","first-page":"396","author":"Torchilin","year":"2003"},{"key":"10.1016\/j.plipres.2016.08.005_bb0435","unstructured":"Melis \u00c7a\u011fda\u015f, Ali Demir Sezer, Seyda Bucak, Liposomes as potential drug carrier systems for drug delivery"},{"key":"10.1016\/j.plipres.2016.08.005_bb0440","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0076-6879(05)91005-7","article-title":"Preparation and characterization of taxane-containing liposomes","volume":"391","author":"Straubinger","year":"2005","journal-title":"Methods Enzymol."},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0445","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: a review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"10.1016\/j.plipres.2016.08.005_bb0450","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1755-148X.2009.00581.x","article-title":"Use of liposomes as drug delivery vehicles for treatment of melanoma","volume":"22","author":"Tran","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0455","author":"Khan"},{"key":"10.1016\/j.plipres.2016.08.005_bb0460","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0169-409X(95)00019-4","article-title":"Therapeutic progress with topical liposome drugs for skin disease","volume":"18","author":"Schmid","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0465","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.plipres.2016.08.005_bb0470","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajps.2013.07.010","article-title":"Development of liposomal formulations: From concept to clinical investigations","volume":"8","author":"Fan","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0475","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3923\/pjbs.2006.1181.1191","article-title":"Liposome as a carrier for advanced drug delivery","volume":"9","author":"Shaheen","year":"2006","journal-title":"Pak. J. Biol. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0480","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drudis.2011.09.015","article-title":"Liposomal drug formulations in cancer therapy: 15years along the road","volume":"17","author":"Slingerland","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.plipres.2016.08.005_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/895986","article-title":"Drug delivery nanoparticles in skin cancers","volume":"895986","author":"Dianzani","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.plipres.2016.08.005_bb0490","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1248\/bpb.18.1234","article-title":"Antitumor activity of doxorubicin encapsulated in poly (ethylene glycol)-coated liposomes","volume":"18","author":"Hosoda","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.plipres.2016.08.005_bb0495","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1359-0294(00)00090-X","article-title":"Liposome application: problems and prospects","volume":"6","author":"Barenholz","year":"2001","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0500","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2009.07.010","article-title":"Novel formulation approaches for optimizing delivery of anticancer drugs based on P-glycoprotein modulation","volume":"14","author":"Bansal","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.plipres.2016.08.005_bb0505","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/13543776.2011.561784","article-title":"The emerging role of p-glycoprotein inhibitors in drug delivery: a patent review","volume":"21","author":"Akhtar","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.plipres.2016.08.005_bb0510","series-title":"Nonviral Vectors for Gene Therapy","first-page":"69","article-title":"Structure and structure-activity relationships of lipid-based gene delivery systems","author":"Lasic","year":"1999"},{"key":"10.1016\/j.plipres.2016.08.005_bb0515","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijpharm.2009.12.061","article-title":"Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro","volume":"389","author":"Krieger","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0520","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2009.10.020","article-title":"Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor","volume":"142","author":"Abu Lila","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0525","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2008.02.005","article-title":"In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin","volume":"127","author":"Watanabe","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0530","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1590\/S0100-879X2011007500091","article-title":"Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy","volume":"44","author":"Muehlmann","year":"2011","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0535","first-page":"136","article-title":"Photo-protection by topical DNA repair enzymes: molecular correlates of clinical studies","volume":"69","author":"Yarosh","year":"1999","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0540","series-title":"Application of Nanotechnology in Drug Delivery","article-title":"Liposomes as potential drug carrier systems for drug delivery","author":"\u00c7a\u011fda\u015f","year":"2014"},{"key":"10.1016\/j.plipres.2016.08.005_bb0545","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/S0142-9612(01)00052-7","article-title":"Intracellular delivery mediated by an ethosomal carrier","volume":"22","author":"Touitou","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.plipres.2016.08.005_bb0550","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","article-title":"Ethosomes novel vesicular carriers for enhanced delivery: characterization and skin penetration properties","volume":"65","author":"Touitou","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0555","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0142-9612(00)00063-6","article-title":"Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes","volume":"21","author":"Dayan","year":"2000","journal-title":"Biomaterials"},{"key":"10.1016\/j.plipres.2016.08.005_bb0560","first-page":"123148","article-title":"Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes","author":"Dubey","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0565","unstructured":"Pinsky, M.A, 2010. \u201cMaterials and Methods for Delivering Antioxidants into the Skin\u201d U.S. Patent 20,100,098,752"},{"key":"10.1016\/j.plipres.2016.08.005_bb0570","unstructured":"Mills, R, Mathur R, Lawrence N. 2007. Mahonia aquifolim extract, Extraction process and pharmaceutical composition containing the same.U.S. Patent 20,070,148,226."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0575","first-page":"113","article-title":"Some properties of N-acyl sarcosinate lipid vesicles","volume":"43","author":"Wallach","year":"1992","journal-title":"J. Soc. Cosmet. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb0580","series-title":"Transdermal and Topical Drug Delivery from Theory to Clinical Practice","author":"Williams","year":"2003"},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0585","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/S0100-879X1999000200006","article-title":"Liposomes: from biophysics to the design of peptide vaccines","volume":"32","author":"Fr\u00e9zard","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0590","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/243232a0","article-title":"Ufasomes are stable particles surrounded by unsaturated fatty acid membranes","volume":"243","author":"GEBICKI","year":"1973","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0595","first-page":"706","article-title":"Ufasomes nano-vesicles-based lyophilized platforms for intranasal delivery of cinnarizine: preparation, optimization, ex-vivo histopathological safety assessment and mucosal confocal imaging","volume":"21","author":"Salama","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0600","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0169-409X(00)00069-7","article-title":"Virosomes: evolution of the liposome as a targeted drug delivery system","volume":"43","author":"Kaneda","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0605","first-page":"163","article-title":"Targeted gene delivery by virosomes","volume":"199","author":"Sarkar","year":"2002","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0610","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.vaccine.2003.08.024","article-title":"Efficient delivery of DNA to dendritic cells mediated by influenza virosomes","volume":"22","author":"Cusi","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.plipres.2016.08.005_bb0615","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1020198908574","article-title":"Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMS","volume":"22","author":"Bungener","year":"2002","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.plipres.2016.08.005_bb0620","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0076-6879(03)73005-5","article-title":"Influenza virosomes in vaccine development","volume":"373","author":"Huckriede","year":"2003","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0625","first-page":"355","article-title":"Drug-carrier and stability properties of the long-lived lipid vesicles cryptosomes, in vitro and in vivo","volume":"2","author":"Cevc","year":"1992","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.plipres.2016.08.005_bb0630","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1021\/jp7095828","article-title":"Compaction process of calf thymus DNA by mixed cationic\u2013zwitterionic liposomes: a physicochemical study","volume":"112","author":"Rodr\u00edguez-Pulido","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.plipres.2016.08.005_bb0635","series-title":"Gene Delivery","author":"Advanced","year":"2003"},{"key":"10.1016\/j.plipres.2016.08.005_bb0640","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1211\/jpp.58.3.0005","article-title":"Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver","volume":"58","author":"Vyas","year":"2006","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.plipres.2016.08.005_bb0645","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10611860701453836","article-title":"Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis","volume":"15","author":"Vyas","year":"2007","journal-title":"J. Drug Target."},{"key":"10.1016\/j.plipres.2016.08.005_bb0650","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/10611860701195395","article-title":"Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting","volume":"15","author":"Gupta","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.plipres.2016.08.005_bb0655","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0973-8398.102930","article-title":"Emulsomes: an emerging vesicular drug delivery system","volume":"6","author":"Gill","year":"2012","journal-title":"Asian J. Pharm."},{"issue":"35","key":"10.1016\/j.plipres.2016.08.005_bb0660","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.2174\/1381612811319350006","article-title":"Nanostructured cubosomes as advanced drug delivery system","volume":"19","author":"Pan","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.plipres.2016.08.005_bb0665","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1039\/B606965G","article-title":"Formation of liquid core polymer shell microcapsules","volume":"2","author":"Yow","year":"2006","journal-title":"Soft Matter"},{"key":"10.1016\/j.plipres.2016.08.005_bb0670","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1074868","article-title":"Colloidosomes: selectively permeable capsules composed of colloidal particles","volume":"298","author":"Dinsmore","year":"2006","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.plipres.2016.08.005_bb0675","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1517\/17425247.3.6.727","article-title":"Transfersomes for transdermal drug delivery","volume":"3","author":"Benson","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0680","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3797\/scipharm.1208-02","article-title":"A novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation","volume":"80","author":"Gupta","year":"2012","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0685","series-title":"Prediction of Percutaneous Penetration","first-page":"226","article-title":"Ultra-high efficiency of drug and peptide transfer through the intact skin by means of novel drug-carriers, transfersomes","volume":"vol 3b","author":"Cevc","year":"1993"},{"key":"10.1016\/j.plipres.2016.08.005_bb0690","unstructured":"Cevc G, Vierl U. NSAID formulations, based on highly adaptable aggregates for improved transport through barriers and topical drug delivery. USP 7473432 B2."},{"key":"10.1016\/j.plipres.2016.08.005_bb0695","unstructured":"Cevc G, Vierl U, Aggregates with increased deformability comprising at least three amphipats for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo especially through the skin. USP 20090155235 A1"},{"key":"10.1016\/j.plipres.2016.08.005_bb0700","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0005-2736(99)00176-5","article-title":"Interactions of elastic and rigid vesicles with human skin in vitro: electron microscopy and two-photon excitation microscopy","volume":"1461","author":"van den Bergh","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plipres.2016.08.005_bb0705","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10601330701885116","article-title":"Formulation and clinical evaluation of ultra deformable liposomes in the topical treatment of psoriasis","volume":"25","author":"Vanaja","year":"2008","journal-title":"Clin. Res. Regul. Aff."},{"key":"10.1016\/j.plipres.2016.08.005_bb0710","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.addr.2003.10.038","article-title":"On the formulation of pH sensitive liposomes with long circulating time","volume":"56","author":"Simoes","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0715","first-page":"219","article-title":"Lipid-based nano-delivery systems for skin delivery of drugs and bioactives","volume":"6","author":"Susan","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0720","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425247.2.2.237","article-title":"Cationic liposomes for gene delivery","volume":"2","author":"Sim\u00f5es","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0725","first-page":"058","article-title":"Cationic lipids used in non-viral gene delivery systems","volume":"2","author":"Uddin","year":"2007","journal-title":"Biotech. Mol. Biol. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0730","first-page":"2431","article-title":"Stealth liposomes: an improved sustained release system for 1-\u03b2-d-arabinofuranosylcytosine","volume":"52","author":"Allen","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0735","first-page":"25","article-title":"Human gene therapy","volume":"392","author":"Anderson","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.plipres.2016.08.005_bb0740","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199345010-00003","article-title":"Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential","volume":"45","author":"Gregoriadis","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.plipres.2016.08.005_bb0745","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/088532820001400405","article-title":"Liposphere based lipoprotein-mimetic delivery system for 6-mercaptopurine","volume":"14","author":"Khopade","year":"2000","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.plipres.2016.08.005_bb0750","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/0929867043456197","article-title":"The vesosome \u2014 a multicompartment drug delivery vehicle","volume":"11","author":"Kisak","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb0755","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1016\/j.vaccine.2006.04.030","article-title":"Development of novel fusogenic vesosomes for transcutaneous immunization","volume":"24","author":"Mishra","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0760","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2013.05.011","article-title":"Formation of artificial multicompartment vesosome and dendrosome as prospected drug and gene delivery carriers","volume":"170","author":"Paleos","year":"2013","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.plipres.2016.08.005_bb0765","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/biot.201200388","article-title":"Automated formation of multicomponent-encapuslating vesosomes using continuous flow microcentrifugation","volume":"8","author":"Jang","year":"2013","journal-title":"Biotechnol. J."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0770","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/187221109789105630","article-title":"New generation of liposomes called archaeosomes based on natural or synthetic Archaeal lipids as innovative formulations for drug delivery","volume":"3","author":"Benvegnu","year":"2009","journal-title":"Recent Pat. Drug Deliv. Formul."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb0775","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/0738-859991229170","article-title":"Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems","volume":"19","author":"Patel","year":"1999","journal-title":"Crit. Rev. Biotechnol."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0780","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0378-1097(97)00294-2","article-title":"Archaeosomes as novel antigen delivery systems","volume":"154","author":"Sprott","year":"1997","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.plipres.2016.08.005_bb0785","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/396068","article-title":"Preparation and characterization of stealth archaeosomes based on a synthetic PEGylated archaeal tetraether lipid","volume":"2011","author":"Barbeau","year":"2011","journal-title":"J. Drug Deliv."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0790","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2007.08.018","article-title":"In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers","volume":"258","author":"Sun","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.plipres.2016.08.005_bb0795","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-5793(91)80699-4","article-title":"Influence of steric barrier activity of amphiphatic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo","volume":"284","author":"Mori","year":"1991","journal-title":"FEBS Lett."},{"key":"10.1016\/j.plipres.2016.08.005_bb0800","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1021\/bi00367a023","article-title":"Target-sensitive immunoliposomes-preparation and characterization","volume":"25","author":"Ho","year":"1986","journal-title":"Biochemical"},{"key":"10.1016\/j.plipres.2016.08.005_bb0805","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0005-2728(01)00165-7","article-title":"p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups","volume":"1511","author":"Torchilin","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plipres.2016.08.005_bb0810","series-title":"Proceeding of the National Academy of Sciences USA","first-page":"14164","article-title":"Brain drug delivery of small molecules using immunoliposomes","volume":"93","author":"Huwyler","year":"1996"},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0815","first-page":"1011","article-title":"Development of hemosomal drug delivery system","volume":"1","author":"Idris","year":"2014","journal-title":"Austin J. Anal. Pharm. Chem."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0820","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/02652040410001673900","article-title":"Encapsulation of ATP into liposomes by different methods: optimization of the procedure","volume":"21","author":"Liang","year":"2004","journal-title":"J. Microencapsul."},{"issue":"5","key":"10.1016\/j.plipres.2016.08.005_bb0825","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1015837321087","article-title":"Adenosine triphosphate liposomes: encapsulation and distribution studies","volume":"7","author":"Xu","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0830","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1166\/jnn.2008.065","article-title":"Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes","volume":"8","author":"Celia","year":"2008","journal-title":"J. Nanosci. Nanotechnol."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0835","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/156720107779314749","article-title":"Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes","volume":"4","author":"Grazia Calvagno","year":"2007","journal-title":"Current Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb0840","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00280-009-0957-1","article-title":"In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer","volume":"64","author":"Cosco","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0845","series-title":"Structural Analysis of \u201cFlexible\u201d Liposome Formulations: New Insights into the Skin-Penetrating Ability of Soft Nanostructures","author":"Ogunsola","year":"2012"},{"key":"10.1016\/j.plipres.2016.08.005_bb0850","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0928-0987(98)00037-2","article-title":"Liposome-skin interactions and their effects on the skin permeation of drugs","volume":"4","author":"Kirjavainen","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0855","first-page":"73","article-title":"The impact of early ADME profiling on drug discovery and development strategy","volume":"5","author":"Wang","year":"2004","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.plipres.2016.08.005_bb0860","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-11-337","article-title":"Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial)","volume":"11","author":"Eckes","year":"2011","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb0865","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/0250-474X.40340","article-title":"Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery","volume":"70","author":"Chandrashekar","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0870","doi-asserted-by":"crossref","unstructured":"Sou K, Chapter 15: advanced drug carriers targeting bone marrow, http:\/\/dx.doi.org\/10.5772\/51206.","DOI":"10.5772\/51206"},{"key":"10.1016\/j.plipres.2016.08.005_bb0875","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ijc.2910620215","article-title":"Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes","volume":"62","author":"Allen","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.plipres.2016.08.005_bb0880","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0885","first-page":"2561","article-title":"Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model","volume":"62","author":"Zhou","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0890","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0022-3565(24)39325-5","article-title":"Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose","volume":"293","author":"Laverman","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.plipres.2016.08.005_bb0895","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0900","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0905","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb0910","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/pharmaceutics6010137","article-title":"Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology","volume":"6","author":"Ait-Oudhia","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.plipres.2016.08.005_bb0915","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(91)90201-I","article-title":"Pharmacokinetics of stealth versus conventional liposomes: effect of dose","volume":"1068","author":"Allen","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plipres.2016.08.005_bb0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002800050855","article-title":"Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice","volume":"43","author":"Newman","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0925","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0031-6997(24)01426-1","article-title":"Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors","volume":"51","author":"Drummond","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0930","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","article-title":"Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy","volume":"88","author":"Papahadjopoulos","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.plipres.2016.08.005_bb0935","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0005-2736(94)90038-8","article-title":"Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes","volume":"1190","author":"Litzinger","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plipres.2016.08.005_bb0940","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002800050894","article-title":"Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines","volume":"43","author":"Zamboni","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0945","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb0950","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-003-0719-4","article-title":"Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma","volume":"53","author":"Zamboni","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.plipres.2016.08.005_bb0955","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/med.2610130504","volume":"13","author":"Singh","year":"1993","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb0960","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-4889(96)00041-9","article-title":"Measurement of endosome pH following folate receptor-mediated endocytosis","volume":"1312","author":"Lee","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"issue":"27","key":"10.1016\/j.plipres.2016.08.005_bb0965","doi-asserted-by":"crossref","first-page":"13602","DOI":"10.1016\/S0021-9258(18)68284-5","article-title":"Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles","volume":"263","author":"Kamen","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb0970","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jps.20457","article-title":"Folate receptor-mediated drug targeting: from therapeutics to diagnostics","volume":"94","author":"Hilgenbrink","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb0975","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2004.01.011","article-title":"Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid\u2013PEG conjugates","volume":"56","author":"Gabizon","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb0980","first-page":"1949","article-title":"Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump","volume":"6","author":"Goren","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0985","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2003.12.028","article-title":"Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma","volume":"213","author":"Turk","year":"2004","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb0990","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/acs.molpharmaceut.5b00663","article-title":"Enhanced cytotoxicity of folic acid-targeted liposomes co-loaded with C6 ceramide and doxorubicin: in vitro evaluation on HeLa, A2780-ADR, and H69-AR cells","volume":"13","author":"Sriraman","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb0995","first-page":"523","article-title":"Encapsulation of vincristine in liposome reduces toxicity and improves anti-tumour efficacy","volume":"5","author":"Boman","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1000","series-title":"Liposomes in Biomedical Applications","first-page":"85","article-title":"Preclinical and clinical activity of liposomal doxorubicin","author":"Boman","year":"1995"},{"key":"10.1016\/j.plipres.2016.08.005_bb1005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0009-3084(86)90078-2","article-title":"The development and application of protein-liposome conjugation techniques","volume":"40","author":"Heath","year":"1986","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.plipres.2016.08.005_bb1010","series-title":"Liposome Technology","first-page":"41","article-title":"Chemical methods for the modification of liposomes with proteins or antibodies","volume":"vol. 3","author":"Hashimoto","year":"1993"},{"key":"10.1016\/j.plipres.2016.08.005_bb1015","series-title":"Liposome Technology","first-page":"29","article-title":"Covalent coupling of monoclonal antibodies and protein A to liposomes: specific interaction with cells in vitro and in vivo","volume":"vol. 3","author":"Leserman","year":"1993"},{"key":"10.1016\/j.plipres.2016.08.005_bb1020","series-title":"Liposome Technology","first-page":"75","article-title":"Immobilization of specific proteins on liposome surface: systems for drug targeting","volume":"vol. 3","author":"Torchilin","year":"1993"},{"key":"10.1016\/j.plipres.2016.08.005_bb1025","series-title":"Drug Targeting: Strategies, Principles, and Applications","article-title":"Antibody conjugation methods for active targeting of liposomes","volume":"vol. 25","author":"Ansell","year":"2000"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb1030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bjc.1992.11","article-title":"Use of photosensitive, antibody directed liposomes to destroy target populations of cells in bone marrow: a potential purging method for autologous bone marrow transplantation","volume":"65","author":"Morgan","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.plipres.2016.08.005_bb1035","first-page":"6214","article-title":"Monoclonal antibody targeting of liposomes to mouse lung in vivo","volume":"49","author":"Hughes","year":"1989","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb1040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJN.S1253","article-title":"Tumor targeting using liposomal antineoplastic drugs","volume":"3","author":"Huwyler","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.plipres.2016.08.005_bb1045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/156800910791190210","article-title":"A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy","volume":"10","author":"Paliwal","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.plipres.2016.08.005_bb1050","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.addr.2013.09.017","volume":"65","author":"Minko","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb1055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2013.00222","article-title":"Tumor targeting via integrin ligands","volume":"3","author":"Marelli","year":"2013","journal-title":"Front Oncol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0076-6879(05)91009-4","volume":"391","author":"Asai","year":"2005","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.canlet.2012.10.007","article-title":"Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin","volume":"1","author":"Shahin","year":"2013","journal-title":"Cancer Lett."},{"issue":"1\u20132","key":"10.1016\/j.plipres.2016.08.005_bb1070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2008.07.012","article-title":"Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo","volume":"363","author":"Song","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.plipres.2016.08.005_bb1075","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1096\/fj.08-117002","article-title":"Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo","volume":"23","author":"Song","year":"2009","journal-title":"FASEB"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb1080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/mp900201v","article-title":"Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy","volume":"7","author":"Fonge","year":"2009","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.plipres.2016.08.005_bb1085","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jmmm.2010.02.019","article-title":"Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells","volume":"322","author":"Creixell","year":"2010","journal-title":"J. Magn. Magn. Mater."},{"key":"10.1016\/j.plipres.2016.08.005_bb1090","article-title":"Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2016.08.005_bb1095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-011-1688-7","article-title":"Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer","volume":"133","author":"Moura","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.plipres.2016.08.005_bb1100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/1061186X.2012.729215","article-title":"Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer","volume":"21","author":"Hare","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.plipres.2016.08.005_bb1105","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1016\/j.biomaterials.2012.07.043","article-title":"Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity","volume":"33","author":"Guo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.plipres.2016.08.005_bb1110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2015.09.059","article-title":"Liposome-based glioma targeted drug delivery enabled by stable peptide ligands","volume":"218","author":"We","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbamem.2009.12.001","article-title":"Design of peptide-targeted liposomes containing nucleic acids","volume":"1798","author":"Santos","year":"2010","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.plipres.2016.08.005_bb1120","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.plipres.2016.08.005_bb1125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1007548826495","article-title":"Cationic polymer based gene delivery systems","volume":"17","author":"De Smedt","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1130","doi-asserted-by":"crossref","unstructured":"L. D. Mayer, P. R. Cullis, and M. B. Bally, The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin, J. Lipid Res., vol. 4, no. 1, pp. 529\u2013553, (199)","DOI":"10.3109\/08982109409037060"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb1135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/17425247.2014.866650","volume":"11","author":"Dicheva","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb1140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2015.01.027","article-title":"Liposome functionalization with copper-free \"click chemistry\"","volume":"28","author":"Oude","year":"2015","journal-title":"J. Control. Release"},{"issue":"5\u20136","key":"10.1016\/j.plipres.2016.08.005_bb1145","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1440-1681.2006.04406.x","article-title":"Art and science of photodynamic therapy","volume":"33","author":"Pervaiz","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb1150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425247.4.2.131","article-title":"Photodynamic therapy and cancer: a brief sightseeing tour","volume":"4","author":"Palumbo","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb1155","series-title":"Advances in Bioengineering","isbn-type":"print","article-title":"Chapter 9: photodynamic nanomedicine strategies in cancer therapy and drug delivery","author":"Ion","year":"2015","ISBN":"https:\/\/id.crossref.org\/isbn\/9789535121411"},{"issue":"11","key":"10.1016\/j.plipres.2016.08.005_bb1160","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1586\/era.10.154","article-title":"Recent advances in the prevention and treatment of skin cancer using photodynamic therapy","volume":"10","author":"Zhao","year":"2010","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"9","key":"10.1016\/j.plipres.2016.08.005_bb1165","doi-asserted-by":"crossref","first-page":"916","DOI":"10.7150\/thno.4571","article-title":"Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics","volume":"2","author":"Josefsen","year":"2012","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb1170","doi-asserted-by":"crossref","DOI":"10.2174\/157341311795542453","volume":"7","author":"Maherani","year":"2011","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1175","unstructured":"Xiaoling Li, Jasti BR. Design of Controlled Release Drug Delivery Systems, McGraw-Hill, Chapter 11, physical targeting approaches to drug targeting, pp 339\u2013375."},{"key":"10.1016\/j.plipres.2016.08.005_bb1180","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1021\/js960135w","article-title":"Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments","volume":"85","author":"Balthasar","year":"1996","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb1185","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(94)00193-9","article-title":"Inverse targeting of drugs to reticuloendothelial system-rich organs by lipid micro-emulsion emulsified with poloxamer 338","volume":"113","author":"Lee","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/mp800218q","article-title":"Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals","volume":"6","author":"Du","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1195","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1016\/j.biomaterials.2013.03.097","article-title":"Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes","volume":"34","author":"Gao","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.plipres.2016.08.005_bb1200","doi-asserted-by":"crossref","first-page":"12905","DOI":"10.1074\/jbc.M900280200","article-title":"Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors","volume":"284","author":"Chang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb1205","first-page":"1479","article-title":"Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery","volume":"19","author":"Li","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1210","first-page":"368","article-title":"Double liposomes mediated dual drug targeting for treatment of Helicobacter pylori infections","volume":"66","author":"Singh","year":"2011","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.plipres.2016.08.005_bb1215","first-page":"205","article-title":"Double-liposome-based dual-drug delivery system as vectors for effective management of peptic ulcer","volume":"22","author":"Jain","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1220","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/bc060080h","article-title":"Smart drug delivery systems: double-targeted ph responsive pharmaceutical nanocarriers","volume":"17","author":"Sawant","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb1225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbamem.2005.02.007","article-title":"Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity","volume":"1711","author":"Laginha","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plipres.2016.08.005_bb1230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000254410","article-title":"The regeneration rate of the water vapor loss of heavily damaged skin","volume":"132","author":"Spruit","year":"1966","journal-title":"Dermatology"},{"key":"10.1016\/j.plipres.2016.08.005_bb1235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1021\/js950219p","article-title":"Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors","volume":"85","author":"Tsai","year":"1996","journal-title":"J. Pharm. Sci."},{"issue":"22","key":"10.1016\/j.plipres.2016.08.005_bb1240","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1073\/pnas.90.22.10504","article-title":"Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery","volume":"90","author":"Prausnitz","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.plipres.2016.08.005_bb1245","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/aic.690210522","article-title":"Drug permeation through human skin: theory and in vitro experimental measurement","volume":"21","author":"Michaels","year":"1975","journal-title":"AIChE J"},{"key":"10.1016\/j.plipres.2016.08.005_bb1250","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-4362.1983.tb02187.x","article-title":"Kinetics of cutaneous drug penetration","volume":"22","author":"Franz","year":"1983","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1255","series-title":"Topical Corticosteroids","first-page":"42","article-title":"Vasoconstrictor assay: specific applications","author":"Stoughton","year":"1992"},{"issue":"3 Suppl.","key":"10.1016\/j.plipres.2016.08.005_bb1260","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/0885-3924(92)90049-N","article-title":"System functionality and physicochemical model of fentanyl transdermal system","volume":"7","author":"Gupta","year":"1992","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.plipres.2016.08.005_bb1265","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jps.2600770605","article-title":"Percutaneous absorption of sulconazole nitrate in man","volume":"77","author":"Franz","year":"1988","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1270","series-title":"Guidance for Industry. Residual Drug in Transdermal and Related Drug Delivery Systems (Draft Guidance)","author":"US Food and Drug Administration","year":"2010"},{"key":"10.1016\/j.plipres.2016.08.005_bb1275","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1467-2494.1987.tb00478.x","article-title":"Physical changes in hydrated skin","volume":"9","author":"Van Den Merwe","year":"1987","journal-title":"Int. J. Cosmet. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1280","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1073\/pnas.0501176102","article-title":"Design principles of chemical penetration enhancers for transdermal drug delivery","volume":"29","author":"Karande","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.plipres.2016.08.005_bb1285","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/81359","article-title":"Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of infl ammation","volume":"6","author":"Rothbard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1290","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt1193","article-title":"Transdermal protein delivery by a co-administered peptide identified via phage display","volume":"24","author":"Chen","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2007.05.031","article-title":"Transdermal delivery enhanced by magainin pore-forming peptide","volume":"122","author":"Kim","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1300","doi-asserted-by":"crossref","first-page":"243452","DOI":"10.1155\/2014\/243452","article-title":"New enlightenment of skin cancer chemoprevention through phytochemicals: in vitro and in vivo studies and the underlying mechanisms","volume":"2014","author":"Singh","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.plipres.2016.08.005_bb1305","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2133.2011.10507.x","article-title":"Roles of the immune system in skin cancer","volume":"165","author":"Rangwala","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1310","unstructured":"Vazhappilly Cijo George, Vijayabhavanath Vijayakumaran Vijesh, Amararathna Inoka Madumani Dehigaspege, Chelakkot Ayshwarya Lakshmi, Kannan Anbarasu, Devanga Ragupathi Naveen Kumar, Radhakrishnan Ethiraj, Rangasamy Ashok Kumar, H P Vasantha Rupasinghe. Mechanism of action of flavonoids in prevention of inflammation-associated skin cancer. Curr. Med. Chem.."},{"issue":"Suppl. 2","key":"10.1016\/j.plipres.2016.08.005_bb1315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1320","unstructured":"Walter A, Sch\u00e4fer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, Sch\u00f6newolf N, Dummer R, Bloch W, Werner S, Beer HD, Knuth A, van den Broek M (2013)."},{"issue":"Suppl. 66","key":"10.1016\/j.plipres.2016.08.005_bb1325","first-page":"5","article-title":"Imiquimod: modes of action","volume":"149","author":"Bilu","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1330","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/ncomms2566","article-title":"Aldara activates TLR7-independent immune defence","volume":"4","author":"Walter","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.plipres.2016.08.005_bb1335","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/archderm.138.11.1498","article-title":"A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses","volume":"138","author":"Stockfleth","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1340","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","article-title":"Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial","volume":"161","author":"Gebauer","year":"2009","journal-title":"Br J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1345","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1542\/peds.2011-0936","article-title":"Cytokine dermatitis and febrile seizure from imiquimod","volume":"129","author":"Mosher","year":"2012","journal-title":"Pediatrics"},{"issue":"17","key":"10.1016\/j.plipres.2016.08.005_bb1350","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/1381612013397113","article-title":"Intercalators as anticancer drugs","volume":"7","author":"Bra\u00f1a","year":"2001","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.plipres.2016.08.005_bb1355","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb1360","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0026-895X(25)10149-1","article-title":"Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells","volume":"45","author":"Fornari","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.plipres.2016.08.005_bb1365","first-page":"2891","article-title":"Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells","volume":"36","author":"Momparler","year":"1976","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.plipres.2016.08.005_bb1370","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ncomms2921","article-title":"Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin","volume":"4","author":"Pang","year":"2013","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.plipres.2016.08.005_bb1375","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nchembio.1811","article-title":"Chemical profiling of the genome with anti-cancer drugs defines target specificities","volume":"11","author":"Pang","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.plipres.2016.08.005_bb1380","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00128071-200708040-00002","article-title":"The role of topical cyclooxygenase-2 inhibitors in skin cancer: treatment and prevention","volume":"8","author":"Zhan","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"issue":"Suppl. 13","key":"10.1016\/j.plipres.2016.08.005_bb1385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2004.08.003","article-title":"Use of liposomal anthracyclines in Kaposi's sarcoma","volume":"31","author":"Krown","year":"2004","journal-title":"Semin. Oncol."},{"issue":"Suppl. 13","key":"10.1016\/j.plipres.2016.08.005_bb1390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.seminoncol.2004.08.005","article-title":"Role of liposomal anthracyclines in the treatment of multiple myeloma","volume":"31","author":"Hussein","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1395","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1400","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0005-2736(02)00661-2","article-title":"Rate of bio-distribution of stealth liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity","volume":"10","author":"Charrois","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plipres.2016.08.005_bb1405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jconrel.2015.08.005","article-title":"Multifunctional liposomes having target specificity, temperature-triggered release, and near-infrared fluorescence imaging for tumor-specific chemotherapy","volume":"28","author":"Kono","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1410","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jddst.2015.10.013","article-title":"In vivo tumor-suppressing efficacy and cell internalization of doxorubicin loaded in liposomes bearing folate","volume":"30","author":"Wang","year":"2015","journal-title":"J. Drug Deliv. Sci. Tech."},{"key":"10.1016\/j.plipres.2016.08.005_bb1415","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jconrel.2015.10.039","article-title":"Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region","volume":"28","author":"Amin","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1420","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1039\/C4CC08746A","article-title":"Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersomes for tumor metastasis therapy","volume":"28","author":"Kong","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.plipres.2016.08.005_bb1425","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2014.07.058","article-title":"Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes","volume":"10","author":"Dicheva","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1430","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijpharm.2014.09.005","article-title":"Enhancement of the anti-tumor effect of DNA vaccination using an ultrasound-responsive mannose-modified gene carrier in combination with doxorubicin-encapsulated PEGylated liposomes","volume":"20","author":"Yoshida","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1435","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18388\/abp.2009_2528","article-title":"Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors","volume":"56","author":"Mitrus","year":"2009","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1440","first-page":"540","article-title":"Clinical phase II study of PEGylated liposomal doxorubicin as second-line treatment in disseminated melanoma","volume":"27","author":"Fink","year":"2004","journal-title":"Onkologie"},{"key":"10.1016\/j.plipres.2016.08.005_bb1445","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s004320000221","article-title":"Angio-sarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy","volume":"127","author":"Wollina","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1450","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s004320000178","article-title":"Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up","volume":"127","author":"Wollina","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1455","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"15","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1460","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/09546630902789326","article-title":"Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders","volume":"20","author":"Moore","year":"2009","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.plipres.2016.08.005_bb1465","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/09546634.2010.507704","article-title":"Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders","volume":"23","author":"Ceilley","year":"2012","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.plipres.2016.08.005_bb1470","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2004.07.045","article-title":"The effects of lyophilization on the stability of liposomes containing 5-FU","volume":"291","author":"Glavas-Dodov","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"489","key":"10.1016\/j.plipres.2016.08.005_bb1475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2015.04.056","article-title":"Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery","volume":"15","author":"Cosco","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1480","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1039\/C5MD00077G","article-title":"Inclusion of new 5-fluorouracil amphiphilic derivatives in liposome formulation for cancer treatment","volume":"6","author":"Petaccia","year":"2015","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.plipres.2016.08.005_bb1485","first-page":"1","article-title":"Nano-vesicular carrier-based formulation for skin cancer targeting: evaluation of cytotoxicity, intracellular uptake, and preclinical anticancer activity","volume":"24","author":"Jain","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.plipres.2016.08.005_bb1490","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/CAD.0b013e3283534051","article-title":"Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study","volume":"23","author":"Puri","year":"2012","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.plipres.2016.08.005_bb1495","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/CAD.0b013e328346c7d6","article-title":"Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release and cytotoxicity analysis","volume":"22","author":"Alvi","year":"2011","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.plipres.2016.08.005_bb1500","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijpharm.2007.11.037","article-title":"Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer","volume":"353","author":"Paolino","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1505","first-page":"237","article-title":"Entrapment of bleomycin in ultra-deformable liposomes","volume":"13","author":"Lau","year":"2003","journal-title":"STP Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1510","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijpharm.2005.04.019","article-title":"Ultra deformable liposomes containing bleomycin: in vitro stability and toxicity on human cutaneous keratinocyte cell lines","volume":"300","author":"Lau","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1515","first-page":"150","article-title":"Development of novel topical drug delivery system containing cisplatin and imiquimod for dual therapy in cutaneous epithelial malignancy","volume":"24","author":"Gupta","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1520","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdermsci.2006.12.011","article-title":"Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intra-tumor drug accumulation against melanomas","volume":"46","author":"Hwang","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1525","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biopha.2015.05.002","article-title":"Improved anti-melanoma effect of a transdermal mitoxantroneethosome gel","volume":"73","author":"Yu","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.plipres.2016.08.005_bb1530","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3109\/1061186X.2012.694887","article-title":"Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis","volume":"20","author":"Bhatia","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.plipres.2016.08.005_bb1535","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/2225-4110.110423","article-title":"Camptothecin-loaded liposomes with \u03b1-melanocyte-stimulating hormone enhance cytotoxicity toward and cellular uptake by melanomas: an application of nanomedicine on natural product","volume":"3","author":"Lin","year":"2013","journal-title":"J. Tradit. Complement Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1540","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001813-199502000-00010","article-title":"Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts","volume":"6","author":"Daoud","year":"1995","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"10.1016\/j.plipres.2016.08.005_bb1545","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1684\/ejd.2013.2155","article-title":"Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects","volume":"23","author":"Crain","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1550","author":"International listings for imiquimod"},{"key":"10.1016\/j.plipres.2016.08.005_bb1555","series-title":"Summary of product characteristics","author":"EMA","year":"2016"},{"key":"10.1016\/j.plipres.2016.08.005_bb1560","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijpharm.2013.06.052","article-title":"Selection of high efficient transdermal lipid vesicle for curcumin skin delivery","volume":"15","author":"Zhao","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1565","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.3390\/molecules17055972","article-title":"Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics","volume":"17","author":"Chen","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.plipres.2016.08.005_bb1570","doi-asserted-by":"crossref","first-page":"11679","DOI":"10.3390\/molecules190811679","article-title":"Review of natural compounds for potential skin cancer treatment","volume":"19","author":"Chinembiri","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.plipres.2016.08.005_bb1575","first-page":"871","article-title":"Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin","volume":"66","author":"Wang","year":"2011","journal-title":"Pharmazie"},{"key":"10.1016\/j.plipres.2016.08.005_bb1580","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10611860400015977","article-title":"Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intra-tumor administrations","volume":"13","author":"Fang","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.plipres.2016.08.005_bb1585","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2005.12.010","article-title":"Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas","volume":"42","author":"Fang","year":"2006","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1590","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3892\/br.2014.310","article-title":"Protective effect of trehalose-loaded liposomes against UVB-induced photo-damage in human keratinocytes","volume":"2","author":"Emanuele","year":"2014","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.plipres.2016.08.005_bb1595","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2119\/2006-00111.Khan","article-title":"Potential of diallyl sulfide bearing pH-sensitive liposomes in chemoprevention against DMBA-induced skin papilloma","volume":"13","author":"Khan","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1600","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/tx900318a","article-title":"The molecular effects of aloe-emodin (AE)\/liposome-AE on human nonmelanoma skin cancer cells and skinpermeation","volume":"22","author":"Chou","year":"2009","journal-title":"Chem. Res. Toxicol."},{"issue":"1472","key":"10.1016\/j.plipres.2016.08.005_bb1605","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-4165(99)00121-X","article-title":"Antiproliferative effect and apoptotic response in vitro of human melanoma cells to liposomes containing the ribosome-inactivating protein luffin","volume":"18","author":"Poma","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"issue":"216","key":"10.1016\/j.plipres.2016.08.005_bb1610","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2015.06.033","article-title":"MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses","volume":"28","author":"Boks","year":"2015","journal-title":"J. Control. Release"},{"issue":"160","key":"10.1016\/j.plipres.2016.08.005_bb1615","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jconrel.2012.02.007","article-title":"Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells","volume":"30","author":"Unger","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1620","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1011-1344(01)00246-9","article-title":"Effect of xenogenic repair enzymes on photo-immunology and photo-carcinogenesis","volume":"65","author":"Stege","year":"2001","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1625","first-page":"4227","article-title":"Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice","volume":"1","author":"Yarosh","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1630","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archderm.1987.01660260111026","article-title":"Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases","volume":"123","author":"Kraemer","year":"1987","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1635","first-page":"693","article-title":"Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer","volume":"148","author":"Puviani","year":"2013","journal-title":"J. Italian Dermatol. Venereol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1640","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00839.x","article-title":"Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced up-regulation of interleukin-10 and, tumor necrosis factor-alpha","volume":"114","author":"Wolf","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1645","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1093\/nar\/20.18.4761","article-title":"Participation of glutamic acid 23 of T4 endonuclease V in the beta-elimination reaction of an abasic site in a synthetic duplex DNA","volume":"20","author":"Hori","year":"1992","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1650","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1755-148X.2009.00643.x","article-title":"Enhancement of DNA repair using topical T4 endonuclease V does not inhibit melanoma formation in Cdk4(R24C\/R24C)\/Tyr-Nras(Q61K) mice following neonatal UVR","volume":"23","author":"Hacker","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1655","unstructured":"National Cancer Institute (NCI), T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant. (ClinicalTrials.govIdentifier:NCT00089180, 2015)"},{"key":"10.1016\/j.plipres.2016.08.005_bb1660","first-page":"S1","article-title":"Repair of cyclobutyl pyrimidine dimers in skin cancer patients treated with liposomes containing T4 endonuclease V","volume":"16","author":"Wolfa","year":"1998","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1665","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/0973-1482.82932","article-title":"Multiple cutaneous malignancies in a patient of Xeroderma pigmentosum","volume":"7","author":"Grampurohit","year":"2011","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.plipres.2016.08.005_bb1670","first-page":"405","article-title":"Repairing DNA damage in Xeroderma pigmentosum: T4N5 lotion and gene therapy","volume":"7","author":"Zahid","year":"2008","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1675","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(00)04214-8","article-title":"Effect of topically applied T4 endonuclease V in liposomes on skin cancer in Xeroderma pigmentosum: a randomized study. Xeroderma pigmentosum study group","volume":"357","author":"Yarosh","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2016.08.005_bb1680","article-title":"Interventions for preventing non-melanoma skin cancers in high-risk groups","volume":"17","author":"Bath-Hextall","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.plipres.2016.08.005_bb1685","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jphotobiol.2004.11.022","article-title":"Evaluation of photolyase (photosome) repair activity in human keratinocytes after a single dose of ultraviolet B irradiation using the comet assay","volume":"79","author":"Decome","year":"2005","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.plipres.2016.08.005_bb1690","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0781.1995.tb00130.x","article-title":"Reduction of ultraviolet-induced skin cancer in mice by topical application of DNA excision repair enzymes","volume":"11","author":"Bito","year":"1995","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.plipres.2016.08.005_bb1695","first-page":"33","article-title":"Strategies used in the clinical trials of gene therapy for cancer","volume":"11","author":"Ajith","year":"2015","journal-title":"J. Exp. Ther. Oncol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1700","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2014.08.021","article-title":"CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojectionarray","volume":"28","author":"Haigh","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.plipres.2016.08.005_bb1705","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1158\/0008-5472.CAN-07-6614","article-title":"Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development","volume":"15","author":"Tran","year":"2008","journal-title":"Cancer Res."},{"issue":"66","key":"10.1016\/j.plipres.2016.08.005_bb1710","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1158\/0008-5472.CAN-06-0809","article-title":"Targeting mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases","volume":"15","author":"Sharma","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1715","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejcb.2014.02.001","article-title":"The role of microRNAs in melanoma","volume":"93","author":"Luo","year":"2014","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1720","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/jgm.1214","article-title":"Bax mRNA therapy using cationic liposomes for human malignant melanoma","volume":"8","author":"Okumura","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1725","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1568011023353903","article-title":"Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy","volume":"2","author":"Casas","year":"2002","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.plipres.2016.08.005_bb1730","first-page":"630","article-title":"In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of amino levulinic acid and its methyl ester","volume":"5","author":"Osiecka","year":"2010","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.plipres.2016.08.005_bb1735","first-page":"474","article-title":"A case study to evaluate the treatment of vitiligo with khellin encapsulated in l-phenylalanine stabilized phosphatidylcholine liposomes in combination with ultraviolet light therapy","volume":"13","author":"de Leeuw","year":"2003","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1740","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/lsm.20739","article-title":"Fluorescence detection and diagnosis of non-melanoma skin cancer at an early stage","volume":"41","author":"de Leeuw","year":"2009","journal-title":"Lasers Surg. Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1745","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijpharm.2008.01.020","article-title":"Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy","volume":"356","author":"Fang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1750","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jphotobiol.2005.03.009","article-title":"Topical use of liposomal copper palmitate formulation blocks porphyrin-induced photosensitivity in rats","volume":"80","author":"Bilgin","year":"2005","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.plipres.2016.08.005_bb1755","first-page":"1","article-title":"Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: preparation and in vitro permeation study","volume":"30","author":"Pierre","year":"2001","journal-title":"BMC Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1760","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejps.2011.07.003","article-title":"Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapy","volume":"18","author":"Oh","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1765","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2133.2000.03711.x","article-title":"The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic acid. Implications in cutaneous photodynamic sensitization","volume":"143","author":"Casas","year":"2000","journal-title":"Br J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1770","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/092986706776360888","article-title":"Aminolevulinic acid derivatives and liposome delivery as strategies for improving 5-aminolevulinic acid-mediated photodynamic therapy","volume":"13","author":"Casas","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.plipres.2016.08.005_bb1775","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jphotobiol.2008.01.009","article-title":"Topical application of temoporfin-loaded invasomes for photodynamic therapy of subcutaneously implanted tumours in mice: a pilot study","volume":"91","author":"Dragicevic-Curic","year":"2008","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.plipres.2016.08.005_bb1780","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.colsurfb.2009.07.005","article-title":"Development of liposomes containing ethanol for skin delivery of temoporfin: characterization and in vitro penetration studies","volume":"74","author":"Dragicevic-Curic","year":"2009","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.plipres.2016.08.005_bb1785","first-page":"38","article-title":"Stability evaluation of temoporfin-loaded liposomal gels for topical application","volume":"1","author":"Dragicevic-Curic","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1790","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1939-1676.2007.tb03020.x","article-title":"Photodynamic therapy of feline cutaneous squamous cell carcinoma using a newly developed liposomal photosensitizer: preliminary results concerning drug safety and efficacy","volume":"21","author":"Buchholz","year":"2007","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.plipres.2016.08.005_bb1795","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1615\/JEnvironPatholToxicolOncol.v26.i2.60","article-title":"Fluorescence monitoring of a topically applied liposomal Temoporfin formulation and photodynamic therapy of non-pigmented skin malignancies","volume":"26","author":"Bendsoe","year":"2007","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1800","doi-asserted-by":"crossref","first-page":"034026","DOI":"10.1117\/1.2743080","article-title":"Fluorescence and absorption assessment of a lipid mTHPC formulation following topical application in a non-melanotic skin tumor model","volume":"12","author":"Johansson","year":"2007","journal-title":"J. Biomed. Opt."},{"key":"10.1016\/j.plipres.2016.08.005_bb1805","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/03639045.2010.529144","article-title":"Improving the topical delivery of zinc phthalocyanine using oleic acid as a penetration enhancer: in vitro permeation and retention","volume":"37","author":"da Silva","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1810","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.dyepig.2013.08.018","article-title":"Preparation, characterization, and in vitro phototoxic effect of zinc phthalocyanine cucurbit[7]uril complex encapsulated into liposomes","volume":"100","author":"Bolfarinia","year":"2014","journal-title":"Dyes Pigments"},{"key":"10.1016\/j.plipres.2016.08.005_bb1815","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1248\/cpb.54.242","article-title":"Enhanced delivery of retinoic acid to skin by cationic liposomes","volume":"54","author":"Kitagawa","year":"2006","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.plipres.2016.08.005_bb1820","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2013.08.019","article-title":"Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photo-stability, biocompatibility and anti-psoriatic activity","volume":"456","author":"Raza","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1825","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00008390-200308000-00003","article-title":"Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy","volume":"13","author":"Ryuke","year":"2003","journal-title":"Melanoma Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1830","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2011.03.068","article-title":"Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin","volume":"30","author":"Manconi","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.plipres.2016.08.005_bb1835","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/eji.200636053","article-title":"Inhibitory effect of the polyinosinic-polycytidylic acid\/cationic liposome on the progression of murine B16F10 melanoma","volume":"36","author":"Fujimura","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1840","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/smll.200701043","article-title":"Functionalized-quantum-dot-liposome hybrids as multimodal nanopartides for cancer","volume":"4","author":"Al-Jamal","year":"2008","journal-title":"Small"},{"key":"10.1016\/j.plipres.2016.08.005_bb1845","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<268::AID-IJC17>3.0.CO;2-1","article-title":"GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide","volume":"12","author":"Pagnan","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.plipres.2016.08.005_bb1850","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1562\/0031-8655(2002)076<0073:CEIMAH>2.0.CO;2","article-title":"Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches","volume":"76","author":"An","year":"2002","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1855","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/19.5.723","article-title":"COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer","volume":"19","author":"Buckman","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.plipres.2016.08.005_bb1860","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.21878","article-title":"Effect of NSAIDs on the recurrence of nonmelanoma skin cancer","volume":"119","author":"Grau","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.plipres.2016.08.005_bb1865","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajps.2013.07.016","article-title":"Enhancement of liposomal stability and cellular drug uptake by incorporating tributyrin into celecoxib-loaded liposomes","volume":"8","author":"Kanga","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.plipres.2016.08.005_bb1870","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/10717544.2012.724472","article-title":"Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib","volume":"19","author":"Bragagni","year":"2012","journal-title":"Drug Deliv."},{"key":"10.1016\/j.plipres.2016.08.005_bb1875","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CAD.0b013e3282f28ffb","article-title":"Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice","volume":"19","author":"Riedel","year":"2008","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.plipres.2016.08.005_bb1880","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11095-012-0856-8","article-title":"Protein antigen adsorption to the DDA\/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics","volume":"30","author":"Hamborg","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.plipres.2016.08.005_bb1885","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1016\/j.vaccine.2014.05.050","article-title":"Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant","volume":"32","author":"Korsholm","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.plipres.2016.08.005_bb1890","first-page":"741","article-title":"Liposomes and diagnostic imaging: the potential to visualize both structure and function","volume":"4","author":"Niesman","year":"2008","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.plipres.2016.08.005_bb1895","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4161\/cbt.5.8.3261","volume":"5","author":"Dicker","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.plipres.2016.08.005_bb1900","series-title":"Biophotonics: Photonic Solutions for Better Health Care V. Brussels, Belgium","author":"Popp","year":"2016"},{"key":"10.1016\/j.plipres.2016.08.005_bb1905","series-title":"Proc. SPIE 9887, Biophotonics: Photonic Solutions for Better Health Care V, 98870S","article-title":"Hyperspectral imaging of skin and lung cancers","author":"Zherdeva","year":"2016"},{"key":"10.1016\/j.plipres.2016.08.005_bb1910","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1740-8261.2000.tb01462.x","article-title":"The role of liposomes in drug delivery and diagnostic imaging: a review","volume":"41","author":"Matteucci","year":"2000","journal-title":"Vet. Radiol. Ultrasound"},{"key":"10.1016\/j.plipres.2016.08.005_bb1915","series-title":"Amyloidosis \u2014 An Insight to Disease of Systems and Novel Therapies","isbn-type":"print","doi-asserted-by":"crossref","DOI":"10.5772\/18602","article-title":"Amyloidosis in the skin","author":"Yamamoto","year":"2011","ISBN":"https:\/\/id.crossref.org\/isbn\/9789533077956"},{"key":"10.1016\/j.plipres.2016.08.005_bb1920","doi-asserted-by":"crossref","DOI":"10.1038\/srep04924","article-title":"Polarization-sensitive hyperspectral imaging in vivo: a multimode dermoscope for skin analysis","volume":"4","author":"Vasefi","year":"2014","journal-title":"Sci. Report."},{"key":"10.1016\/j.plipres.2016.08.005_bb1925","unstructured":"Herman C. Three-dimensional thermal imaging for the detection of skin lesions and other natural and abnormal conditions, USP 201 3011 6573 A1"},{"key":"10.1016\/j.plipres.2016.08.005_bb1930","series-title":"ASME 2010 Summer Bioengineering Conference, Naples, Florida, USA","isbn-type":"print","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1115\/SBC2010-19193","article-title":"Detection of skin cancer using transient\/thermal imaging. Paper SBC2010-19193","author":"\u00c7eting\u00fcl","year":"2010","ISBN":"https:\/\/id.crossref.org\/isbn\/9780791844038"},{"issue":"51","key":"10.1016\/j.plipres.2016.08.005_bb1935","doi-asserted-by":"crossref","DOI":"10.3791\/2679","article-title":"Quantitative visualization and detection of skin cancer using dynamic thermal imaging","volume":"51","author":"Herman","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.plipres.2016.08.005_bb1940","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.infrared.2014.09.017","article-title":"Dynamic infrared imaging for skin cancer screening, proceedings of international conference on quantum structures","volume":"70","author":"Godoy","year":"2015","journal-title":"Infrared Phys. Technol."},{"issue":"12","key":"10.1016\/j.plipres.2016.08.005_bb1945","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/ijd.12159","article-title":"Uses of non-invasive imaging in the diagnosis of skin cancer: an overview of the currently available modalities","volume":"52","author":"Wassef","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.plipres.2016.08.005_bb1950","series-title":"Confocal Laser Microscopy \u2014 Principles and Applications in Medicine, Biology, and the Food Sciences","article-title":"Confocal laser scanning microscopy as a tool for the investigation of skin drug delivery systems and diagnosis of skin disorders","author":"Rossetti","year":"2013"},{"issue":"1","key":"10.1016\/j.plipres.2016.08.005_bb1955","doi-asserted-by":"crossref","first-page":"42","DOI":"10.12788\/j.sder.2016.011","article-title":"Radiographic imaging for skin cancer","volume":"35","author":"Belkin","year":"2016","journal-title":"Semin. Cutan. Med. Surg."}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782716300248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782716300248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T01:26:37Z","timestamp":1749605197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782716300248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":391,"alternative-id":["S0163782716300248"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2016.08.005","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}